Skip to content

EDESA BIOTECH, INC.: 10-Q filed 2015-02-09

What EDESA BIOTECH, INC. reported in its quarterly report filed 2015-02-09 (fiscal Q1 2015): 31 published measures, 97 facts as tagged in accession 0001144204-15-007126.

This filing

Form
10-Q (quarterly report)
Filed
2015-02-09
Fiscal period
fiscal Q1 2015
Accession
0001144204-15-007126 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EDESA BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-12-3113,425,793USD
At 2014-09-3014,827,715USD
At 2014-08-3114,473,962USD
At 2013-09-3016,071,983USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-12-314,188,951USD
At 2014-09-304,362,980USD
At 2014-08-316,773,329USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-12-319,236,842USD
At 2014-09-3010,464,735USD
At 2014-08-317,700,633USD
At 2013-09-306,536,786USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-12-3112,763,533USD
At 2014-09-3013,769,953USD
At 2014-08-3113,427,404USD
At 2013-12-3116,725,570USD
At 2013-09-3015,478,038USD
At 2013-08-317,859,889USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-1,343,477USD92
2014-09-01 to 2014-09-301,127,904USD30
2013-10-01 to 2013-12-31-5,577,190USD92
2013-09-01 to 2013-09-30-240,389USD30

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-10-01 to 2014-12-3138,849USD92
2014-09-01 to 2014-09-3013,477USD30
2013-10-01 to 2013-12-31209,129USD92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-10-01 to 2014-12-31212,661USD92
2014-09-01 to 2014-09-3052,786USD30
2013-10-01 to 2013-12-3158,825USD92
2013-09-01 to 2013-09-3013,839USD30

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-12-31-33,835,763USD
At 2014-09-30-32,492,286USD
At 2014-08-31-33,620,190USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-10-01 to 2014-12-3179,461,013shares92
2014-09-01 to 2014-09-3078,675,750shares30
2013-10-01 to 2013-12-3173,978,736shares92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-10-01 to 2014-12-3179,461,013shares92
2014-09-01 to 2014-09-3087,140,449shares30
2013-10-01 to 2013-12-3173,978,736shares92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-0.02USD/shares92
2014-09-01 to 2014-09-300.01USD/shares30
2013-10-01 to 2013-12-31-0.08USD/shares92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-0.02USD/shares92
2014-09-01 to 2014-09-300.01USD/shares30
2013-10-01 to 2013-12-31-0.08USD/shares92

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-10-01 to 2014-12-319,800USD92
2014-09-01 to 2014-09-303,800USD30
2013-10-01 to 2013-12-31800USD92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-12-31389,654USD
At 2014-09-30388,340USD
At 2014-08-31387,392USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-10-01 to 2014-12-3186,865USD92
2014-09-01 to 2014-09-3036,509USD30
2013-10-01 to 2013-12-31468,717USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-12-3113,020,239USD
At 2014-09-3014,423,475USD
At 2014-08-3114,070,670USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-12-313,955,344USD
At 2014-09-30672,174USD
At 2014-08-311,420,666USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-10-01 to 2014-12-311,538,075USD92
2014-09-01 to 2014-09-30505,109USD30
2013-10-01 to 2013-12-311,754,432USD92
2013-09-01 to 2013-09-30351,189USD30

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2014-12-31134,308USD
At 2014-09-3034,891USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2013-09-01 to 2013-09-3034,930USD30

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-10-01 to 2014-12-31418,821USD92
2014-09-01 to 2014-09-30178,280USD30
2013-10-01 to 2013-12-31548,225USD92
2013-09-01 to 2013-09-30203,367USD30

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-12-3179,546,650shares
At 2014-09-3079,419,850shares
At 2014-08-3178,268,850shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-12-31945,452USD
At 2014-09-30906,603USD
At 2014-08-31893,126USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-12-31555,798USD
At 2014-09-30518,263USD
At 2014-08-31505,734USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-10-01 to 2014-12-31942,153USD92
2014-09-01 to 2014-09-30293,130USD30
2013-10-01 to 2013-12-311,021,130USD92
2013-09-01 to 2013-09-30112,892USD30

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-10-01 to 2014-12-3137,535USD92
2014-09-01 to 2014-09-3012,529USD30
2013-10-01 to 2013-12-3131,811USD92

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-09-01 to 2013-09-30386USD30

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-8,263USD92
2014-09-01 to 2014-09-301,584,027USD30
2013-10-01 to 2013-12-31-3,880,783USD92

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2014-10-01 to 2014-12-319,800USD92
2014-09-01 to 2014-09-30800USD30
2013-10-01 to 2013-12-31800USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-8,045USD92
2014-09-01 to 2014-09-30-12,352USD30

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-3199,417USD92
2014-09-01 to 2014-09-3034,891USD30
2013-10-01 to 2013-12-31-158,284USD92

Inspect the source

Entity
EDESA BIOTECH, INC. / CIK 0001540159
Captured
2026-09-20T09:17:32.413Z
SEC response SHA-256
0f44de1ccf1eff46a1af17dc21d4a3bb38216bbf46e813f5a136d29e08bfd65d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001540159.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))